Skip to main content
. 2020 Mar 24;13:605–612. doi: 10.2147/JPR.S237833

Figure 2.

Figure 2

Incidence of abdominal pain (A), diarrhea (B), nausea (C), and vomiting (D) by eGFR at baseline (COMPOSE-1/COMPOSE-2/COMPOSE-3 safety population).

Abbreviations: eGFR, estimated glomerular filtration rate; NAL, naldemedine, RI, renal impairment.